This webinar will provide investors, researchers, and industry participants with direct access to Lantern’s next-generation AI platform, which is designed to transform the speed, cost, and precision of oncology drug discovery - particularly in rare cancers.
During the live demonstration, the team will showcase how withZeta.ai functions as a multi-agentic AI co-scientist, capable of:
- Executing complex research workflows in real time
- Synthesizing insights across clinical, molecular, and scientific datasets
- Accelerating hypothesis generation, molecule design, and trial strategy
The session is structured to provide both technical visibility into the platform’s capabilities and strategic insight into its commercial potential as a scalable, subscription-based revenue stream.
Building on a Landmark Platform Launch
The webinar follows Lantern’s recent commercial launch of withZeta.ai. Developed from Lantern’s proprietary RADR® platform and informed by years of real-world oncology research, withZeta.ai integrates:
- A proprietary rare cancer ontology spanning hundreds of cancer subtypes
- Multi-database querying across clinical trials, literature, and molecular datasets
- Advanced AI models for molecular design and predictive analytics
The platform is now commercially available under introductory, academic, and enterprise subscription tiers, representing a non-dilutive revenue opportunity for shareholders.
